Mesoporous Silica Nanoparticles for Improved Solubility and Bioavailability of Pazopanib in the Treatment of Renal Cell Carcinoma
- 10 March 2026
- journal article
- research article
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 274
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- A Systematic Evaluation of the Dosing Regimens for Approved Targeted Therapies and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma From a Project OPTIMUS PerspectiveThe Journal of Clinical Pharmacology, 2025
- Molecular Encapsulation of Abiraterone Acetate in 2,6 Di-O-Methyl-β-Cyclodextrin for Solubility Enhancement: Synthesis, Characterization, In Vitro Drug Release, and Molecular DockingBioNanoScience, 2024
- Solubility Enhancement of Aripiprazole via Mesoporous Silica: Preparation, Characterization, In vitro Drug Release, and Solubility DeterminationJournal of Pharmaceutical Innovation, 2023
- Differential sensitivity of renal carcinoma cells to doxorubicin and epigenetic therapeutics depends on the genetic backgroundMolecular and Cellular Biochemistry, 2021
- Synthesis, biological evaluation, and molecular docking analysis of phenstatin based indole linked chalcones as anticancer agents and tubulin polymerization inhibitorsBioorganic Chemistry, 2020
- Octanol-Water Partition Constant2020
- Mesoporous Silica and Organosilica Nanoparticles: Physical Chemistry, Biosafety, Delivery Strategies, and Biomedical ApplicationsAdvanced Healthcare Materials, 2017
- Pazopanib: a Review in Advanced Renal Cell CarcinomaTargeted Oncology, 2017
- Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized DosingClinical Pharmacokinetics, 2017
- Insoluble drug delivery strategies: review of recent advances and business prospectsActa Pharmaceutica Sinica B, 2015